Thyroid hormone-induced angiogenesis

Current Cardiology Reviews

Volumn 5, Issue 1, 2009, Pages 12-16

  Davis, Paul J ^a   Davis, Faith B ^a   Mousa, Shaker A ^b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CELL SURFACE RECEPTOR; DIIODOTHYROPROPIONIC ACID; GC 1; IODOTHYRONINE; LEVOTHYROXINE; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; NANOPARTICLE; POLYGLACTIN; TETRAIODOTHYROACETIC ACID; THYROID HORMONE; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL OCCLUSION; BRAIN; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; HEART; HEART FAILURE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPOTHYROIDISM; ISCHEMIA; LIMB ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGLUTINATION; THYROID MEDULLARY CARCINOMA; WOUND HEALING;

EID: 65649128964     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309787048158     Document Type: Review

References (62)

1. Tomanek RJ, Doty MK, Sandra A. Early coronary angiogenesis in response to thyroxine. Growth characteristics and upregulation of basic fibroblast growth factor. Circ Res 1998; 82: 587-593.
2. Tomanek RJ, Busch TL. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec 1998; 251: 44-49.
3. Wang X, Zheng W, Christensen LP, et al. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol 2003; 284: H613-618.
4. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558.
5. Kuzman JA, Tang Y, Vogelsang KA, et al. Thyroid hormone analog, diiodothyropropionic acid (DITPA), exerts beneficial effects on chamber and cellular remodeling in cardiomyopathic hamsters. Can J Physiol Pharmacol 2007; 85: 3121-318.
6. Schlenker EH, Hora M, Liu Y, et al. Effects of thyroidectomy, T4, and DITPA replacement on brain blood vessel density in adult rats. Am J Physiol 2008; 294: R1504-1509.
7. Liu Y, Redetzke RA, Said S, et al. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol 2008; 294:H2137-2142.
8. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50.
9. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93: 1351-1358.
10. Davis FB, Mousa SA, O'Connor L, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 94: 1500-1506.
11. Mousa SA, O'Connor L, Davis FB, et al. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 2006; 147: 1602-1607.
12. Mousa SA, Davis FB, Mohamed S, et al. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 2006; 25: 407-413.
13. Bergh JJ, Lin H-Y, Lansing L, et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146: 2864-2871.
14. Mousa SA, O'Connor LJ, Bergh JJ, et al. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 2005; 46: 356-360.
15. Yen PM, Ando S, Feng X, et al. Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol 2006; 246: 121-127.
16. Tomanek RJ, Butters CA, Zimmerman MB. Initiation of cardiac hypertrophy in response to thyroxine is not limited by age. Am J Physiol (Heart Circ Physiol) 1993; 264: H1041-H1047.
17. Pennock GD, Raya TE, Bahl JJ. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther 1992; 263:163-169.
18. Morkin E, Ladenson P, Goldman S, et al. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 2004; 37: 1137-1146.
19. Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-3064.
20. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 2005; 146: 4425-4430.
21. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-949.
22. Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 2007; 5: 314-323.
23. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-21788.
24. Van Lonkhuyzen DR, Hollier BG, Shooter GK, et al. Chimeric vitronectin:insulin-like growth factor proteins enhance cell growth and migration through co-activation of receptors. Growth Factors 2007; 25: 295-308.
25. Chen CP, Lee MY, Huang JP, et al. Trafficking of multipotent mesenchymal stromal cells from maternal circulation through the placenta involves vascular endothelial growth factor receptor-1 and integrins. Stem Cells 2008; 26: 550-561.
26. Lin H-Y, Davis FB, Gordinier JK, et al. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol 1999; 276: C1014-1024.
27. D'Arezzo S, Incerpi S, Davis FB, et al. Rapid nongenomic effects of 3,5,3′-triiodo-L-thyronine on the intracellular pH of L-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways. Endocrinology 2004; 145: 5694-5703.
28. Fliegel L. Molecular biology of the myocardial Na+/H+ exchanger. J Mol Cell Cardiol 2008; 44: 228-237.
29. Lei J, Mariash CN, Bhargava M, et al. T3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. Am J Physiol 2008; 294: L749-L754.
30. Davis PJ, Davis FB, Lin H-Y. Promotion by thyroid hormone of cytoplasm-to-nucleus shuttling of thyroid hormone receptors. Steroids 2008; 73: 1013-1017.
31. Hiroi Y, Kim H-H, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006; 103: 14104-14109.
32. Lin H-Y, Martino LJ, Wilcox BD, et al. Potentiation by thyroid hormone of human IFN-γ-induced HLA-DR expression. J Immunol 1998; 161: 843-849.
33. Lin H-Y, Shih A, Davis FB, et al. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J 1999; 338: 427-432.
34. Shih A, Zhang S, Cao HJ, et al. Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-α are mediated by 3′,5′-cyclic adenosine 5′-monophosphate-dependent protein kinase II. Endocrinology 2004; 145: 1708-1717.
35. 3), GC-1, or diiodothyropropionic acid (DITPA). Thyroid 2007; 17, (Suppl 1), S-99.
36. Davis PJ, Davis FB, Lin H-Y. L-Thyroxine acts as a hormone as well as a prohormone at the cell membrane. Immun Endocrinol Metab Agents Med Chem 2006; 6: 235-240.
37. Davis PJ, Davis FB, Cody V. Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab 2005; 16: 429-435.
38. Lameloise N, Siegrist-Kaiser C, O'Connell M, et al. Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol 2001; 144: 145-154.
39. Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008; 29: 211-218.
40. Browe DM, Baumgarten CM. EGFR kinase regulates volume-sensitive chloride current elicited by integrin stretch via PI-3K and NADPH oxidase in ventricular myocytes. J Gen Physiol 2006; 127: 237-251.
41. Liao Y, Asakura M, Takashima S, et al. Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochem Biophys Res Commun 2005; 327: 1083-1087.
42. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559-567.
43. El Eter E, Rebbaa H, Alkayali A, Mousa SA. Role of thyroid hormone analogues in angiogenesis and the development of collaterals in rabbit hind limb ischemia model. J Thrombosis Thrombolysis 2007; 5: (suppl 1), 375.
44. Bockhorn M, Frilling A, Benko T, et al. Tri-iodothyronine as a stimulator of liver regeneration after partial and subtotal hepatectomy. Eur Surg Res 2007; 39: 58-63.
45. Mousa SA, Bergh JJ, Dier E, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008; 11: 183-190.
46. Lin H-Y, Zhang S, West BL, et al. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-β1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 2003; 42: 7571-7579.
47. Tang H-Y, Lin H-Y, Zhang S, et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004; 145: 3265-3272.
48. Moro L, Marra E, Capuano F, et al. Thyroid hormone treatment of hypothyroid rats restores the regenerative capacity and the mitochondrial membrane permeability properties of the liver after partial hepatectomy. Endocrinology 2004; 145: 5121-5128.
49. Moeller LC, Cao X, Dumitrescu AM, et al. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nucl Recept Signal 2006; 4: 1-4.
50. Darnell JE Jr. Interferon research: impact on understanding transcriptional control. Curr Top Microbiol Immunol 2007; 316: 155-163.
51. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059-20063.
52. Bartoli M, Gu X, Tsai NT, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 2000; 275: 33189-33192.
53. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-5560.
54. Citores L, Bai L, Sørensen V, et al. Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus. J Cell Physiol 2007; 212: 148-156.
55. Funamoto M, Fujio Y, Kunisada K, et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 2000; 275: 10561-10566.
56. Friesema EC, Jansen J, Visser TJ. Thyroid hormone transporters. Biochem Soc Trans 2005; 33: 228-232.
57. Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 2007; 21: 277-305.
58. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006; 116: 2571-2579.
59. Köhrle J. Thyroid hormone transporters in health and disease. Best Pract Res Clin Endocrinol Metab 2007; 21: 173-191.
60. Farwell AP, Dubord-Tomasetti SA, Pietrzykowski AZ, et al. Dynamic nongenomic actions of thyroid hormone in the developing rat brain. Endocrinology 2006; 147: 2567-2574.
61. Lombardi A, Lanni A, de Lange P, et al. Acute administration of 3,5-diiodo-L-thyronine to hypothyroid rats affects bioenergetic parameters in rat skeletal muscle mitochondria. FEBS Lett 2007; 581: 5911-5916.
62. Yulcin M, Lansing L, Bharali DJ, et al. Tetrac and nanoparticulate tetrac arrest growth and inhibit tumor angiogenesis in xenografts of human medullary carcinoma of the thyroid. Abstract, 79th Annual Meeting of the American Thyroid Association, Chicago, IL, 2008. (Thyroid 2008; 18: in press).